These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10746004)

  • 1. [Mechanisms of action of repaglinide at a cellular level].
    Thomsen MK
    Diabetes Metab; 1999 Dec; 25 Suppl 7():11-3. PubMed ID: 10746004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
    Owens DR; Cozma LS; Luzio SD
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
    Owens DR; Luzio SD; Ismail I; Bayer T
    Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
    Nattrass M; Lauritzen T
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes.
    Owens DR
    Eur J Clin Invest; 1999 Jun; 29 Suppl 2():30-7. PubMed ID: 10383608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
    Moses R
    Expert Opin Pharmacother; 2000 Dec; 1(7):1455-67. PubMed ID: 11249478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of early insulin secretion and its impact on glycaemic regulation.
    Garber AJ
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S32-7. PubMed ID: 11063282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and clinical experience with repaglinide.
    Massi-Benedetti M; Damsbo P
    Expert Opin Investig Drugs; 2000 Apr; 9(4):885-98. PubMed ID: 11060717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Repaglinide in combination therapy in type 2 diabetes].
    Moses R
    Diabetes Metab; 1999 Dec; 25 Suppl 7():26-7. PubMed ID: 10746009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes.
    Landgraf R; Frank M; Bauer C; Dieken ML
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S38-44. PubMed ID: 11063283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide.
    Balfour JA; Faulds D
    Drugs Aging; 1998 Aug; 13(2):173-80. PubMed ID: 9739505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
    Landgraf R
    Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
    Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
    Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus.
    Guay DR
    Pharmacotherapy; 1998; 18(6):1195-204. PubMed ID: 9855316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.
    Damsbo P; Marbury TC; Hatorp V; Clauson P; Müller PG
    Diabetes Res Clin Pract; 1999 Aug; 45(1):31-9. PubMed ID: 10499883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repaglinide dose response? A clinician's viewpoint.
    Schade DS
    Diabetes Technol Ther; 1999; 1(3):257-8. PubMed ID: 11475270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.